U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C11H10O5S
Molecular Weight 254.259
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MENADIONE BISULFITE

SMILES

CC1(CC(=O)C2=CC=CC=C2C1=O)S(O)(=O)=O

InChI

InChIKey=WIXFIQKTHUVFDI-UHFFFAOYSA-N
InChI=1S/C11H10O5S/c1-11(17(14,15)16)6-9(12)7-4-2-3-5-8(7)10(11)13/h2-5H,6H2,1H3,(H,14,15,16)

HIDE SMILES / InChI

Molecular Formula C11H10O5S
Molecular Weight 254.259
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/3927923 | https://www.ncbi.nlm.nih.gov/pubmed/18935165 | https://www.ncbi.nlm.nih.gov/pubmed/26212258

Menadione bisulfite is a water-soluble analog of Vitamin K3. Pharmacologic studies on menadione bisulfate indicad that its toxicity is relatively low. In man, doses approximately ten times as great as those generally recommended for therapeutic use, given daily for a period of one week. Redox cycling compounds, such as menadione, have the potential to effectively mitigate the toxicity of organophosphorus pesticides including parathion. Menadione bisulfite behaved as a competitive inhibitor of chicken muscle aldose reductase.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Aldose reductase (Gallus gallus)
0.025 mM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
10 mg 10 times / day multiple, oral
Highest studied dose
Dose: 10 mg, 10 times / day
Route: oral
Route: multiple
Dose: 10 mg, 10 times / day
Sources:
unhealthy, 56 – 85
Health Status: unhealthy
Age Group: 56 – 85
Sex: M
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Structures of the PutA peripheral membrane flavoenzyme reveal a dynamic substrate-channeling tunnel and the quinone-binding site.
2014 Mar 4
Patents

Patents

Sample Use Guides

5 mg. Therapy, averaging thirty days, was continued until the withdrawal of metlication produced no recurrence of symptoms.
Route of Administration: Oral
In Vitro Use Guide
Addition of menadione bisulfite (3 mM) alone to the perfusate increased oxygen uptake by 20-30 uM/g/hr. In the presence of ethanol, maximal increases in oxygen uptake due to menadione bisulfite were much larger (about 90 uM/g/hr), and lactate dehydrogenase release occurred earlier and reached higher maximal values (330 units/g/hr).
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:13:40 GMT 2025
Edited
by admin
on Mon Mar 31 18:13:40 GMT 2025
Record UNII
I2BE1ZEN8I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MENADIONE BISULFITE
Common Name English
2-NAPHTHALENESULFONIC ACID, 1,2,3,4-TETRAHYDRO-2-METHYL-1,4-DIOXO-
Preferred Name English
Code System Code Type Description
FDA UNII
I2BE1ZEN8I
Created by admin on Mon Mar 31 18:13:40 GMT 2025 , Edited by admin on Mon Mar 31 18:13:40 GMT 2025
PRIMARY
CHEBI
63930
Created by admin on Mon Mar 31 18:13:40 GMT 2025 , Edited by admin on Mon Mar 31 18:13:40 GMT 2025
PRIMARY
PUBCHEM
8536
Created by admin on Mon Mar 31 18:13:40 GMT 2025 , Edited by admin on Mon Mar 31 18:13:40 GMT 2025
PRIMARY
SMS_ID
300000029211
Created by admin on Mon Mar 31 18:13:40 GMT 2025 , Edited by admin on Mon Mar 31 18:13:40 GMT 2025
PRIMARY
CAS
130-36-9
Created by admin on Mon Mar 31 18:13:40 GMT 2025 , Edited by admin on Mon Mar 31 18:13:40 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT